Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

Slides:

Advertisements

Similar presentations

Oral Glucose Tolerance Test as a Breath Challenge Diagnostic Tool in Lung Cancer (1)* Alkoby Layah (3) Abud Hawa Manal (1) Bar Yair (4) Cancilla John(1)

Advertisements

Breath Analysis For Lung Cancer Early Detection Ori Liran a, Manal Abud-Hawa b, Maya Ilouze a,c, Naomi Gai-Mor a, Shlomi Dekel a, Alon Ben-Nun d, Amir.

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Erratum Journal of Thoracic Oncology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav.

Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data.

Frank Detterbeck, MD Journal of Thoracic Oncology

Pulmonary Metastasectomy: A Survey of Current Practice Amongst Members of the European Society of Thoracic Surgeons Eveline Internullo, MD, Stephen D.

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

A Primer on Health Economic Evaluations in Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

The Number of Pulmonary Metastases: Influence on Practice and Outcome

S768I Mutation in EGFR in Patients with Lung Cancer

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Nivolumab-Induced Granulomatous Inflammation of the Pleura

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Pulmonary Metastasectomy in Breast Cancer

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

European Lung Cancer Conference (ELCC) 2016 Organisation

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Non-invasive Breath Analysis of Pulmonary Nodules

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Role of the Wnt Signaling Pathway and Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Haval Balata, MBChB, MRCP, Kwun M. Fong, M. B. B. S

Presentation transcript:

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System Dekel Shlomi, MD, Manal Abud, MSc, Ori Liran, MD, Jair Bar, MD, Naomi Gai-Mor, MSc, Maya Ilouze, PhD, Amir Onn, MD, Alon Ben- Nun, MD, Hossam Haick, PhD, Nir Peled, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 10, Pages 1544-1551 (October 2017) DOI: 10.1016/j.jtho.2017.06.073 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Discriminant factor analysis plots calculated from the responses of the nanoarray sensors for benign pulmonary nodules and early lung cancer. Each point represents one patient. The positions of the mean values are marked with an unfilled square, the boxes correspond to the first and third quartiles, and the error bars correspond to the SDs. CV1, first canonical variable (see Text). Journal of Thoracic Oncology 2017 12, 1544-1551DOI: (10.1016/j.jtho.2017.06.073) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Discriminant factor analysis plot calculated from the responses of the nanoarray sensors for patients with lung cancer with and without the EGFR mutation. Each point represents one patient. The positions of the mean values are marked with an unfilled square, the boxes correspond to the first and third quartiles, and the error bars correspond to the SDs. CV1, first canonical variable (see Text). Journal of Thoracic Oncology 2017 12, 1544-1551DOI: (10.1016/j.jtho.2017.06.073) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions